[Results of treatment based on endocrine therapy for bone metastasis from breast cancer].
Breast cancer patients with bone metastases at times survive for comparatively long periods, though complete cure is rare. The aim of the present study is to assess the value of endocrine therapy in the management of metastatic breast cancer patients. Of the 18 patients, the response rate (CR + PR) was 39% and the fifty percent-survival was 35 months. Improvement in symptoms and performance status was seen in 78% and 33% of the patients, respectively satisfactory palliation could be achieved with endocrine therapy for patients with metastatic breast cancer.
Sakurai
T
T
Division of Surgery, Kawasaki Municipal Ida Hospital.
Tatematsu
H
H
Yamataka
K
K
Yamamoto
T
T
Kawahara
H
H
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary*; D001943:Breast Neoplasms / Q000473:pathology*; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary*; D003520:Cyclophosphamide / Q000008:administration & dosage; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists; D006801:Humans; D008525:Medroxyprogesterone / Q000008:administration & dosage; D008875:Middle Aged; D010166:Palliative Care; D045167:Progesterone Congeners / Q000008:administration & dosage; D011788:Quality of Life; D015996:Survival Rate
D045167:Progesterone Congeners; D007987:Gonadotropin-Releasing Hormone; D015251:Epirubicin; D003520:Cyclophosphamide; D008525:Medroxyprogesterone